Therapy Detail

Therapy Name Mycophenolate mofetil
Synonym
Therapy Description

Cellcept (mycophenolate mofetil) is metabolized to mycophenolic acid, which interferes with proliferation of B- and T-lymphocytes, resulting in immunosuppresion (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mycophenolate mofetil Cellcept Cellcept (mycophenolate mofetil) is metabolized to mycophenolic acid, which interferes with proliferation of B- and T-lymphocytes, resulting in immunosuppresion (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting
NCT01529827 Phase II Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting
NCT00003553 Phase II Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer Unknown status
NCT01619761 Phase I Rituximab Fludarabine + Lenalidomide + Melphalan Mycophenolate mofetil Tacrolimus Natural Killer (NK) Cells in Cord Blood Transplantation Recruiting
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated
NCT00305682 Phase II Sirolimus Mycophenolate mofetil anti-thymocyte globulin Cyclophosphamide Fludarabine Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Active, not recruiting
NCT02756572 Phase I Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia Recruiting
NCT01760655 Phase II Tacrolimus Cyclophosphamide + Fludarabine + Thiotepa Mycophenolate mofetil Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Recruiting
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting
NCT01701986 Phase Ib/II Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Recruiting